PMV Pharmaceuticals reports news as a precision oncology company developing small molecule therapies that target p53. Its recurring updates center on rezatapopt, an oral product candidate designed to reactivate mutant p53 in tumors with the TP53 Y220C mutation, and on the PYNNACLE clinical trial in advanced solid tumors, including ovarian cancer.
Company announcements also cover clinical data presentations and publications, FDA designation activity, periodic financial results, research and development spending tied to rezatapopt, cash runway commentary, and board governance changes.
PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2024 financial results and provided an update on the PYNNACLE clinical trial. Key points include:
1. Enrollment is on track for the Phase 2 monotherapy portion of PYNNACLE, with over 60% of sites activated across the U.S., Europe, and Asia-Pacific.
2. The company expects an interim analysis from Phase 2 monotherapy by mid-2025 and anticipates an NDA filing by the end of 2026.
3. Cash position of $212.9 million as of June 30, 2024, providing an expected runway to the end of 2026.
4. Net loss for Q2 2024 was $1.2 million, significantly reduced from $17.4 million in Q2 2023 due to the sale of New Jersey accumulated net operating losses.
5. R&D expenses increased to $14.6 million in Q2 2024, while G&A expenses decreased to $5.5 million.
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company, announced participation in two major investor conferences in June 2024. David H. Mack, Ph.D., CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent PMV at the Jefferies Global Healthcare Conference on June 6 and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12. Both sessions will include a fireside chat format. Live audio webcasts and archived replays will be accessible online at the company's Events & Presentations page.
Foundation Medicine and PMV Pharmaceuticals have partnered to develop FoundationOne®CDx, a genomic profiling test, as a companion diagnostic for PMV Pharma’s investigational therapy, rezatapopt. Rezatapopt targets the TP53 Y220C mutation found in about 1% of solid tumors, often deemed undruggable despite its prevalence in 50% of cancers. This collaboration utilizes Foundation Medicine's real-world data and genomic tests to support PMV Pharma's clinical trials. Rezatapopt received Fast Track designation from the FDA and is undergoing Phase 2 trials.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported financial results and corporate highlights for Q1 2024. The company dosed the first patient in the Phase 2 PYNNACLE trial for rezatapopt, a potential treatment for advanced solid tumors. Phase 1 data for rezatapopt in advanced ovarian cancer was presented at the 2024 SGO Annual Meeting. The company ended Q1 with $213.1 million in cash, providing expected cash runway to end of 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.